Online inquiry

IVTScrip™ mRNA-Anti-ERBB2, MGAH-22(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ11583MR)

This product GTTS-WQ11583MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets ERBB2 gene. The antibody can be applied in Gastric Cancer research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Chimeric
RefSeq NM_001005862.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2064
UniProt ID P04626
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ERBB2, MGAH-22(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ11583MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3720MR IVTScrip™ mRNA-Anti-MSLN, BAY 94-9343(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA BAY 94-9343
GTTS-WQ15481MR IVTScrip™ mRNA-Anti-MAPT, UCB-0107(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA UCB-0107
GTTS-WQ14438MR IVTScrip™ mRNA-Anti-IGF1R, RO4858696-000(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA RO4858696-000
GTTS-WQ11715MR IVTScrip™ mRNA-Anti-IL13, MILR1444A(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA MILR1444A
GTTS-WQ3961MR IVTScrip™ mRNA-Anti-CD3E&FCRL5, BFCR-4350-A(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BFCR-4350-A
GTTS-WQ2098MR IVTScrip™ mRNA-Anti-IL17A, AIN457(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA AIN457
GTTS-WQ8066MR IVTScrip™ mRNA-Anti-CD33, h2H12ec(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA h2H12ec
GTTS-WQ14946MR IVTScrip™ mRNA-Anti-PDCD1, SHR-1210(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA SHR-1210
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW